CharlesAKunosMDPhD

Radiation Oncology • Lexington, KY

Assistant Professor of Radiation Oncology, Case West Res University

Join to view full profile

Dr. Kunos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kunos' full profile

Already have an account?

Office
800 Rose St
Rm C114
Lexington, KY 40536
Phone+1 859-257-7618

Fax+1 859-257-4060
Is this information wrong?

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Radiation Oncology, 2002 - 2006
The MetroHealth System/Case Western Reserve UniversityInternship, Internal Medicine, 2001 - 2002
Case Western Reserve University School of MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2023 - 2025
KY State Medical License 2020 - 2024
OH State Medical License 2001 - 2024
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer Start of enrollment: 2005 Apr 01
Withdrawn
Phase 1
Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies Start of enrollment: 2006 Mar 01
Completed
Phase 1
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer Start of enrollment: 2009 Jul 01
Completed
Phase 2
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2009 Nov 01
Active, not recruiting
Phase 3
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Start of enrollment: 2011 Feb 01
Completed
Phase 2
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 3
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer Start of enrollment: 2012 Dec 06
Completed
Phase 2
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Start of enrollment: 2012 Nov 01
Completed
Phase 3
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma Start of enrollment: 2012 Dec 20
Completed
Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer Start of enrollment: 2013 Mar 22
Recruiting
Phase 2, Phase 3
Randomized Phase II Study of Intravenous 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine® NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed With Stage IB-IVA Cervical Cancer and S Start of enrollment: 2013 Apr 01
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck Start of enrollment: 2013 Aug 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Stereotactic Body Radiation Therapy for Gynecologic Malignancies: A Case-Based Radiosurgery Society Practice Review.
Colton Ladbury, Mark H Sueyoshi, Nellie M Brovold, Ritesh Kumar, Therese Y Andraos, Emile Gogineni, Minsun Kim, Ann Klopp, Kevin Albuquerque, Charles Kunos, Eric Leung...> ;Practical Radiation Oncology. 2023 Oct 22
Leveraging Radiopharmaceutical Programmatic Collaboration for Management of Pretherapy and On-treatment Urinary Incontinence.
Charles A Kunos, Bryan P Lemieux, Kimyli Recca, M Elizabeth Oates, Riham H El Khouli> ;Health Physics. 2023 Oct 1
1 citations
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Eduardo Gonzalez-Ochoa, Michael Milosevic, Bradley Corr, James L Abbruzzese, Eugenia Girda, Rachel W Miller, Jennifer Croke, Helen Mackay, Yeh Chen Lee, Valerie Boweri...> ;International Journal of Gynecological Cancer. 2023 Aug 7
A case report of typhlitis during novel use of ropidoxuridine-capecitabine-radiotherapy for treatment-naïve rectal cancer.
Charles A Kunos, Richard Piekarz, Jerry M Collins, Timothy J Kinsella> ;Cancer Chemotherapy and Pharmacology. 2023 Aug 1
Human gastrin- releasing peptide receptor expression in women with uterine cervix cancer.
Charles A Kunos, Denise Fabian, Dana Napier, Mark S Stonecypher, Ravyn M Duncan, Jason Hurt> ;Frontiers in Oncology. 2023 Jan 1
Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky.
Charles A Kunos, Denise Fabian, Dava W Piecoro, Dana Napier, Rachel W Miller, Frederick R Ueland> ;Frontiers in Oncology. 2023 Jan 1
Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer.
Charles A Kunos, Denise Fabian, Tricia Fredericks, Lauren Baldwin, Charles Dietrich, Rachel W Miller, Frederick R Ueland> ;Frontiers in Oncology. 2023 Jan 1
1 citations
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Cristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, Barbara Burtness, Christine H Chung, Curtis R Pickering, Carole Fakhry, Quynh Thu Le, Sue S Yom, Thomas J Gallow...> ;Journal of the National Cancer Institute. 2022 Dec 8
5 citations
Current gaps and opportunities in screening, prevention, and treatment of cervical cancer.
Bobbie J Rimel, Charles A Kunos, Nikeya Macioce, Sarah M Temkin> ;Cancer. 2022 Dec 1
A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases.
Zin W Myint, Riham El Khouli, Bryan Lemieux, Donglin Yan, William H St Clair, Xiaoqi Liu, Charles A Kunos> ;BMC Cancer. 2022 Apr 15
3 citations
Adding Base Excision Repair Inhibitor TRC102 to standard Pemetrexed-Platinum-Radiation in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of a ...
Tithi Biswas, Afshin Dowlati, Charles A Kunos, John J. Pink, Nancy L. Oleinick, Shakun Malik, Pingfu Fu, Shufen Cao, Debora S. Bruno, David L. Bajor, Monaliben Patel, ...> ;Clinical Cancer Research. 2021 Nov 5
2 citations
National Cancer Institute support for targeted alpha-emitter therapy.
Julie A Hong, Martin W. Brechbiel, Jeff Buchsbaum, Christie A Canaria, C. Norman Coleman, Freddy E. Escorcia, Michael Graham Espey, Charles A. Kunos, Frank I. Lin, Dee...> ;European Journal of Nuclear Medicine and Molecular Imaging. 2021 Aug 11
3 citations
Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy.
Emilie Roncali, Jacek Capala, Stanley H Benedict, Gamal Akabani, Bryan Bednarz, Vikram Bhadrasain, Wesley E. Bolch, Jeffrey C. Buchsbaum, Norman Coleman, Yuni K. Dewar...> ;Journal of Nuclear Medicine. 2021 Aug 1
3 citations
Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.
Salma K. Jabbour, Terence M. Williams, Mutlay Sayan, Eric D. Miller, Jaffer A. Ajani, Andrew C. Chang, Norman Coleman, Wael El-Rifai, Michael G. Haddock, David H. Ilso...> ;Journal of the National Cancer Institute. 2021 Jun 1
51 citations
NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endomet...
William Small, Walter R. Bosch, Mathew M. Harkenrider, Jonathan B. Strauss, Nadeem R. Abu-Rustum, Kevin Albuquerque, Sushil Beriwal, Carien L. Creutzberg, Patricia J. ...> ;International Journal of Radiation Oncology, Biology, Physics. 2021 Feb 1
98 citations
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Stephanie Lheureux, Mihaela C. Cristea, Jeff Bruce, Swati Garg, Michael Cabanero, Gina Mantia-Smaldone, Alexander B. Olawaiye, Susan Ellard, Johanne I Weberpals, Andre...> ;Lancet. 2021 Jan 23
2 citations
A New Generation of "Magic Bullets" for Molecular Targeting of Cancer.
Jacek Capala, Charles A. Kunos> ;Clinical Cancer Research. 2021 Jan 15
2 citations
Characterization of Uterine Cervix Cancers in Women from Appalachian Kentucky.
Charles A Kunos, Denise Fabian, Mahesh Kudrimoti, Rachel W Miller, Frederick R Ueland, Marcus E Randall> ;Frontiers in Oncology. 2021 Jan 1
28 citations
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
Jonathan W. Riess, Paul Frankel, David Shackelford, Mark Dunphy, Ramsey D. Badawi, Lorenzo Nardo, Simon R. Cherry, Ian Lanza, Joel Reid, Wilson I. Gonsalves, Charles A...> ;Clinical Lung Cancer. 2021 Jan 1
7 citations
Radiopharmaceutical Validation for Clinical Use.
Charles A. Kunos, Rodney Howells, Aman Chauhan, Zin W. Myint, Mark E. Bernard, Riham H. El Khouli, Jacek Capala> ;Frontiers in Oncology. 2021 Mar 3
8 citations
Radiopharmaceutical Chemistry and Drug Development-What's Changed?
Charles A. Kunos, David A. Mankoff, Michael K. Schultz, Stephen A. Graves, Daniel A. Pryma> ;Seminars in Radiation Oncology. 2021 Jan 1
2 citations
Clinical Study of Using Biometrics to Identify Patient and Procedure.
Jason W. Sohn, Haksoo Kim, S. B. Park, Soyoung Lee, James I. Monroe, Thomas B. Malone, Timothy J. Kinsella, Min Yao, Charles A. Kunos, Simon S. Lo, Robert Shenk, Mitch...> ;Frontiers in Oncology. 2020 Dec 1
5 citations
Phase 0 Radiopharmaceutical-Agent Clinical Development.
Charles A. Kunos, Larry V Rubinstein, Jacek Capala, Michael A McDonald> ;Frontiers in Oncology. 2020 Aug 18
Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
Charles A. Kunos, Jacek Capala> ;Pharmaceuticals. 2020 Sep 30
2 citations
In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine
Anand Joshi, Brian F. Kiesel, Nupur Chaphekar, Reyna Jones, Jianxia Guo, Charles A. Kunos, Sarah Taylor, Edward Chu, Raman Venkataramanan, Jan H. Beumer> ;Cancer Chemotherapy and Pharmacology. 2020 Sep 28
Join now to see all

Abstracts/Posters

Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in ...
Charles Kunos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Coming Soon? New Treatments in Ovarian Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018

Press Mentions

Markey Cancer Center Study Shows Potential for New Radiopharmaceutical Cancer TreatmentFebruary 24th, 2023
Radiation Drugs Hunt and Kill Cancer CellsJune 8th, 2021
Radiopharmaceuticals: Radiation Therapy Enters the Molecular AgeOctober 26th, 2020